Cochrane · systematic review · CD008531
Combination chemotherapy versus single‐agent chemotherapy during preoperative chemoradiation for resectable rectal cancer
Resende, HM, Jacob, LFP, Quinellato, LV, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
ColorectalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 28.6%Low 0 · 0%Moderate 3 · 42.9%High 2 · 28.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Combination chemotherapy compared with single‐agent chemotherapy for resectable rectal cancer
Population: people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (3 years) Combination chemotherapy vs single‐agent chemotherapy | HR 0.94 [0.59, 1.48] | 1 study · 598 participants | Very low |
Disease‐free survival (3 years) Combination chemotherapy vs single‐agent chemotherapy | HR 0.88 [0.65, 1.18] | 1 study · 598 participants | Very low |
Complete response rate after preoperative chemoradiation (ypCR) Combination chemotherapy vs single‐agent chemotherapy | OR 1.23 [1.04, 1.46] | 4 studies · 3875 participants | High |
Toxicity ‐ early adverse events G3/4 Combination chemotherapy vs single‐agent chemotherapy | OR 2.07 [1.31, 3.27] | 4 studies · 3875 participants | Moderate |
Metastases intra‐abdominal Combination chemotherapy vs single‐agent chemotherapy | OR 0.46 [0.21, 1.01] | 3 studies · 2567 participants | Moderate |
Radiotherapy compliance Combination chemotherapy vs single‐agent chemotherapy | OR 0.32 [0.14, 0.75] | 3 studies · 2567 participants | Moderate |
Chemotherapy compliance Combination chemotherapy vs single‐agent chemotherapy | OR 0.36 [0.26, 0.52] | 2 studies · 1331 participants | High |